Barclays Maintains Overweight on Alnylam Pharmaceuticals, Lowers Price Target to $450

Benzinga · 2d ago
Barclays analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Overweight and lowers the price target from $527 to $450.